Back to Search Start Over

Clinical and Genetic Characterization of 153 Patients with Persistent or Transient Congenital Hyperinsulinism

Authors :
Joose Raivo
Mannisto Jme
Timo Otonkoski
H. Huopio
Maleeha Maria
Laakso
Teemu Kuulasmaa
Helsinki One Health (HOH)
Centre of Excellence in Stem Cell Metabolism
HUS Children and Adolescents
Children's Hospital
Timo Pyry Juhani Otonkoski / Principal Investigator
University of Helsinki
Helsinki University Hospital Area
Source :
The Journal of Clinical Endocrinology & Metabolism. 105:e1686-e1694
Publication Year :
2020
Publisher :
The Endocrine Society, 2020.

Abstract

Context Major advances have been made in the genetics and classification of congenital hyperinsulinism (CHI). Objective To examine the genetics and clinical characteristics of patients with persistent and transient CHI. Design A cross-sectional study with the register data and targeted sequencing of 104 genes affecting glucose metabolism. Patients Genetic and phenotypic data were collected from 153 patients with persistent (n = 95) and transient (n = 58) CHI diagnosed between 1972 and 2015. Of these, 86 patients with persistent and 58 with transient CHI participated in the analysis of the selected 104 genes affecting glucose metabolism, including 10 CHI-associated genes, and 9 patients with persistent CHI were included because of their previously confirmed genetic diagnosis. Main outcome measures Targeted next-generation sequencing results and genotype–phenotype associations. Results Five novel and 21 previously reported pathogenic or likely pathogenic variants in ABCC8, KCNJ11, GLUD1, GCK, HNF4A, and SLC16A1 genes were found in 68% (n = 65) and 0% of the patients with persistent and transient CHI, respectively. KATP channel mutations explained 82% of the mutation positive cases. Conclusions The genetic variants found in this nationwide CHI cohort are in agreement with previous studies, mutations in the KATP channel genes being the major causes of the disease. Pathogenic CHI-associated variants were not identified in patients who were both diazoxide responsive and able to discontinue medication within the first 4 months. Therefore, our results support the notion that genetic testing should be focused on patients with inadequate response or prolonged need for medication.

Details

ISSN :
19457197 and 0021972X
Volume :
105
Database :
OpenAIRE
Journal :
The Journal of Clinical Endocrinology & Metabolism
Accession number :
edsair.doi.dedup.....def39c6919ce2c40c2abb17f72f5114b